Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | PYGB | P11216 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.30 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022110 | 0.85 | ALDH1A1 (0.34) | SMN1; SMN2JAK2MITFMTNR1AMTNR1B | |
| SCHEMBL21381973 | 0.85 | ALDH1A1 (0.34) | SMN1; SMN2JAK2MITFMTNR1AMTNR1B | |
| SCHEMBL23150450 | 0.85 | ALDH1A1 (0.34) | SMN1; SMN2JAK2MITFMTNR1AMTNR1B | |
| SCHEMBL23150451 | 0.85 | ALDH1A1 (0.34) | SMN1; SMN2JAK2MITFMTNR1AMTNR1B | |
| SCHEMBL31332321 | 0.81 | USP30 (0.34) | SMN1; SMN2JAK2MITFMTNR1AMTNR1B | |
| SCHEMBL20137461 | 0.79 | CTSK (0.38) | SMN1; SMN2CTSKTRPV1CNR1CNR2 | |
| SCHEMBL3612617 | 0.77 | SMN1; SMN2 (0.36) | SMN1; SMN2CTSK | |
| SCHEMBL1841363 | 0.76 | USP2 (0.40) | SMN1; SMN2CTSKTRPV1CNR1CNR2 | |
| SCHEMBL23210140 | 0.75 | MTNR1A (0.31) | MTNR1AMTNR1B | |
| SCHEMBL23152267 | 0.75 | MTNR1A (0.31) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| CN-102143746-A | CDK modulators | EXELIXIS INC | 2011-08-03 | — | — | CN | disclosed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | SMN1; SMN2 1814/4885JAK2 125/4885MITF 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.